BIOMAT Database Logo BIOMAT Database Logo

Auranofin in juvenile rheumatoid arthritis. An open label, non-controlled study. 1984

O Garcia-Morteo, and M E Suarez-Almazor, and J A Maldonado-Cocco, and R Cuttica, and S Abate

An open label, non-controlled trial of six-month duration was designed to determine the safety and efficacy of auranofin in the treatment of 13 children with polyarticular JRA. Adverse reactions were observed in 5 of the 13 patients (38%) but only in one was it serious enough to discontinue treatment. None of the patients developed diarrhea or hematologic abnormalities. Therapeutic response was evaluated in the 11 patients who completed the six-month treatment. According to the final overall assessment 9 of the 11 children had improved, one remained unchanged and one worsened. After four months of treatment serum gold levels in 11 patients ranged between 28 and 59 micrograms/dl, with a mean value of 34 micrograms/dl. There was no correlation between serum gold levels and the frequency and severity of side effects.

UI MeSH Term Description Entries
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006046 Gold A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
D006051 Aurothioglucose A thioglucose derivative used as an antirheumatic and experimentally to produce obesity in animals. Gold Thioglucose,Aureotan,Auromyose,Aurothioglucose, Sodium Salt, beta-D Isomer,Aurothioglucose, beta-D Isomer,Gold-50,Solganal,Solganal B Oleosum,Solganol,Thioglucosoaurate,Aurothioglucose, beta D Isomer,B Oleosum, Solganal,Gold 50,Gold50,Oleosum, Solganal B,Thioglucose, Gold,beta-D Isomer Aurothioglucose
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D001171 Arthritis, Juvenile Arthritis in children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent. Arthritis, Juvenile Chronic,Arthritis, Juvenile Idiopathic,Arthritis, Juvenile Rheumatoid,Childhood Arthritis,PCJIA,PJIA Polyarticular Juvenile Idiopathic Arthritis,Polyarticular Juvenile Idiopathic Arthritis,Polyarticular-Course Juvenile Idiopathic Arthritis,Still's Disease, Juvenile-Onset,Enthesitis-Related Arthritis, Juvenile,Juvenile Chronic Arthritis,Juvenile Idiopathic Arthritis,Juvenile Rheumatoid Arthritis,Juvenile-Onset Still Disease,Juvenile-Onset Stills Disease,Oligoarthritis, Juvenile,Polyarthritis, Juvenile, Rheumatoid Factor Negative,Polyarthritis, Juvenile, Rheumatoid Factor Positive,Psoriatic Arthritis, Juvenile,Still Disease, Juvenile-Onset,Systemic Arthritis, Juvenile,Arthritides, Childhood,Arthritis, Childhood,Arthritis, Juvenile Enthesitis-Related,Arthritis, Juvenile Psoriatic,Arthritis, Juvenile Systemic,Childhood Arthritides,Chronic Arthritis, Juvenile,Enthesitis Related Arthritis, Juvenile,Idiopathic Arthritis, Juvenile,Juvenile Arthritis,Juvenile Enthesitis-Related Arthritis,Juvenile Oligoarthritis,Juvenile Onset Still Disease,Juvenile Onset Stills Disease,Juvenile Psoriatic Arthritis,Juvenile Systemic Arthritis,Juvenile-Onset Still's Disease,Rheumatoid Arthritis, Juvenile,Still Disease, Juvenile Onset,Still's Disease, Juvenile Onset,Stills Disease, Juvenile-Onset
D001310 Auranofin An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious. Crisinor,Ridaura,Ridauran,SK&F D 39162,SK&F-39162,SK&F 39162,SK&F39162

Related Publications

O Garcia-Morteo, and M E Suarez-Almazor, and J A Maldonado-Cocco, and R Cuttica, and S Abate
Auranofin therapy for juvenile rheumatoid arthritis: results of the five-year open label extension trial.
August 1991, The Journal of rheumatology,
O Garcia-Morteo, and M E Suarez-Almazor, and J A Maldonado-Cocco, and R Cuttica, and S Abate
An open label study to establish dosing recommendations for nabumetone in juvenile rheumatoid arthritis.
April 2003, The Journal of rheumatology,
O Garcia-Morteo, and M E Suarez-Almazor, and J A Maldonado-Cocco, and R Cuttica, and S Abate
Auranofin in the treatment of juvenile rheumatoid arthritis.
January 1983, The Journal of pediatrics,
O Garcia-Morteo, and M E Suarez-Almazor, and J A Maldonado-Cocco, and R Cuttica, and S Abate
Early experiences with auranofin in juvenile rheumatoid arthritis.
December 1983, The American journal of medicine,
O Garcia-Morteo, and M E Suarez-Almazor, and J A Maldonado-Cocco, and R Cuttica, and S Abate
An European open multicentre trial with auranofin in rheumatoid arthritis.
March 1984, Clinical rheumatology,
O Garcia-Morteo, and M E Suarez-Almazor, and J A Maldonado-Cocco, and R Cuttica, and S Abate
Longterm auranofin therapy in patients with juvenile rheumatoid arthritis.
August 1986, The Journal of rheumatology,
O Garcia-Morteo, and M E Suarez-Almazor, and J A Maldonado-Cocco, and R Cuttica, and S Abate
An open trial of auranofin (oral gold preparation) in rheumatoid arthritis.
September 1986, The Journal of the Association of Physicians of India,
O Garcia-Morteo, and M E Suarez-Almazor, and J A Maldonado-Cocco, and R Cuttica, and S Abate
Auranofin therapy in juvenile rheumatoid arthritis: a 48-week phase II study.
January 1986, Scandinavian journal of rheumatology. Supplement,
O Garcia-Morteo, and M E Suarez-Almazor, and J A Maldonado-Cocco, and R Cuttica, and S Abate
Rheumatoid arthritis treatment with weekly leflunomide: an open-label study.
February 2004, The Journal of rheumatology,
O Garcia-Morteo, and M E Suarez-Almazor, and J A Maldonado-Cocco, and R Cuttica, and S Abate
The efficacy and safety of auranofin in the treatment of juvenile rheumatoid arthritis. A long-term open study.
August 1988, Arthritis and rheumatism,
Copied contents to your clipboard!